Cisplatin-induced hair cell loss in zebrafish (Danio rerio) lateral line.
We have used time-lapse imaging to study cisplatin-induced hair cell death in lateral line neuromasts of zebrafish larvae in vivo. We found that cisplatin-induced hair cell death occurred much more slowly than had been shown to occur in aminoglycoside-induced hair cell death. By prelabeling hair cells with FM1-43FX, and assessing hair cell damage, it was established that cisplatin causes hair cell loss in the lateral line in a dose-dependent fashion. The kinetics of hair cell loss during exposure to different concentrations of cisplatin was also assessed and it was found that the onset of hair cell loss correlated with the accumulated dose of cisplatin. These data demonstrate the feasibility and repeatability of cisplatin damage protocols in the zebrafish lateral line and set the stage for future evaluations of modulation of cisplatin-induced hair cell death.
Ou
Henry C
HC
Virginia Merrill Bloedel Hearing Research Center, University of Washington, Box 357923, Seattle, WA 98195, USA. henryou@u.washington.edu
Raible
David W
DW
Rubel
Edwin W
EW
D000818:Animals; D016923:Cell Death; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D006198:Hair Cells, Auditory / Q000187:drug effects*; D007700:Kinetics; D007814:Larva / Q000187:drug effects; D053403:Lateral Line System / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D015203:Reproducibility of Results; D013997:Time Factors; D015027:Zebrafish / Q000254:growth & development*
D002945:Cisplatin
Hear Res. 1996 Dec 1;102(1-2):90-8
8951454
Hear Res. 1997 Feb;104(1-2):1-14
9119753
ORL J Otorhinolaryngol Relat Spec. 1994 Nov-Dec;56(6):315-20
7838482
Scanning Microsc. 1994 Mar;8(1):97-106
7973504
Cancer Chemother Pharmacol. 1988;21(3):185-90
3129204
Cancer. 1984 Oct 1;54(7):1269-75
6088023
Cancer Treat Rep. 1982 Jan;66(1):19-23
7198012
Clin Toxicol. 1978;13(4):469-78
747905
J Laryngol Otol. 1993 Jul;107(7):585-9
15125271
Laryngoscope. 2004 Mar;114(3):533-7
15091230
Gene. 2004 Mar 17;328:113-20
15019990
J Assoc Res Otolaryngol. 2003 Dec;4(4):565-78
14605921
J Comp Neurol. 2000 May 29;421(2):189-98
10813781
Hear Res. 2000 May;143(1-2):171-81
10771194
Hear Res. 2000 Apr;142(1-2):34-40
10748326
Hear Res. 1999 Dec;138(1-2):13-28
10575111
Hear Res. 2003 Dec;186(1-2):47-56
14644458
J Assoc Res Otolaryngol. 2003 Jun;4(2):219-34
12943374
Science. 2003 Jul 4;301(5629):96-9
12805553
World J Urol. 1998;16(2):155-62
12073232
Lab Invest. 2002 May;82(5):585-96
12003999
Ann N Y Acad Sci. 1999 Nov 28;884:389-409
10842609
J Comp Neurol. 2007 Jun 1;502(4):522-43
17394157
Hear Res. 2000 Jun;144(1-2):147-56
10831873
Hear Res. 2000 Jun;144(1-2):157-67
10831874
Cancer Chemother Pharmacol. 1996;39(1-2):131-7
8995510
Hear Res. 2007 Apr;226(1-2):157-67
17113254
Mol Pharmacol. 2006 Oct;70(4):1390-4
16847145
Hear Res. 2006 Mar;213(1-2):25-33
16459035
Environ Toxicol Chem. 2006 Feb;25(2):597-603
16519324
Hear Res. 2005 Oct;208(1-2):79-88
16014323
Cancer Res. 2004 Dec 15;64(24):9217-24
15604295
Hear Res. 2004 Dec;198(1-2):137-43
15567610
Pharmacol Toxicol. 1997 Oct;81(4):173-9
9353848
Eur Arch Otorhinolaryngol. 1997;254(6):281-6
9248736
Cancer Chemother Pharmacol. 1997;40(1):11-8
9137523
J Neurosci. 1995 Jul;15(7 Pt 2):5079-87
7623136